Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,101 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,794 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02781883 | Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | recruiting | Phase 2 | 108 | Bio-Path Holdings, Inc.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06865352 | Safety and Preliminary Efficacy of Donor-derived Anti-leukemia Cytotoxic T Lymphocytes for the Prevention of Leukemia Relapse in Children Given Haploidentical Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 15 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Mar 7, 2025 |
| clinicaltrials |
| NCT02396134 | Vaccine Therapy in Reducing the Frequency of Cytomegalovirus Events in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04126681 | A Pivotal Study of HQP1351 in Patients With Chronic Myeloid Leukemia in Chronic Phase | completed | Phase 2 | 144 | Ascentage Pharma Group Inc.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04980885 | A Trial of AK117 (Anti-CD47 Antibody) in Patients With Acute Myeloid Leukemia | active not recruiting | Phase 1 / Phase 2 | 68 | AkesoINDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02828358 | Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement | completed | Phase 2 | 78 | National Cancer Institute (NCI)NIH | 4 | Feb 27, 2025 | clinicaltrials |
| NCT03686345 | Midostaurin Associated With Standard Chemotherapy in Patients With Core-binding Factor Leukemia(AML FLT3) | terminated | Phase 2 | 34 | Niguarda HospitalOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT06299462 | PTCy and ATG for MSD and MUD Transplants | recruiting | Phase 1 / Phase 2 | 50 | Instituto Nacional de Cancer, BrazilOTHER_GOV | 1 | Feb 25, 2025 | clinicaltrials |
| NCT01701843 | Cromoglicate in Mastocytosis | terminated | Phase 2 | 7 | LEO PharmaINDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04905407 | Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | terminated | Phase 2 | 66 | Syros PharmaceuticalsINDUSTRY | 2 | Feb 24, 2025 | clinicaltrials |
| NCT06453902 | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | recruiting | Phase 2 | 40 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03839446 | Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy | completed | Phase 2 | 16 | Robert Redner, MDOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06827899 | Veneclax, Chidaniline Combined With Azacitidine Followed by Decitabine + MAG Regimen in the Treatment of Elderly Untreated AML | recruiting | Phase 2 | 66 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT06151080 | Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FL | recruiting | Phase 2 | 38 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06158399 | AZA Combined With RCHOP in P53-mutated DLBCL. | recruiting | Phase 2 | 52 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT05881265 | Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia | recruiting | Phase 2 | 30 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT00390793 | Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. | completed | Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04281498 | Combined Ruxolitinib and Enasidenib in Patients With Accelerated/Blast-phase Myeloproliferative Neoplasm or Chronic-phase Myelofibrosis With an IDH2 Mutation | completed | Phase 2 | 6 | John MascarenhasOTHER | 2 | Feb 4, 2025 | clinicaltrials |
| NCT04342962 | Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia | terminated | Phase 2 | 25 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT01261312 | SGI-110 in Participants With Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) | completed | Phase 1 / Phase 2 | 414 | Astex Pharmaceuticals, Inc.INDUSTRY | 2 | Jan 23, 2025 | clinicaltrials |
| NCT05601726 | First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients(ODYSSEY) | recruiting | Phase 1 / Phase 2 | 36 | Advanced BioDesignINDUSTRY | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783478 | NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial(NKLMA) | not yet recruiting | Phase 2 | 98 | Hospital de Clinicas de Porto AlegreOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT06783790 | Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT | recruiting | Phase 2 | 20 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT02398825 | Activity and Risk Profile of Ponatinib in Chronic Phase Patients With Chronic Myeloid Leukemia Resistant to Imatinib | terminated | Phase 2 | 14 | Gruppo Italiano Malattie EMatologiche dell'AdultoOTHER | 1 | Jan 17, 2025 | clinicaltrials |
| NCT06754540 | Azacitidine Combined with Donor Lymphocyte Infusion for Acute Myeloid Leukemia Post-transplant Relapse Prevention. | not yet recruiting | Phase 2 | 51 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jan 17, 2025 | clinicaltrials |
| NCT03092674 | Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | completed | Phase 2 / Phase 3 | 76 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2025 | clinicaltrials |
| NCT04914676 | Accelerated Dose Schedule of Cytarabine Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML) in Complete Remission | terminated | Phase 2 | 5 | University of FloridaOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06765915 | Avapritinib Maintenance for AML With KIT Mutations | not yet recruiting | Phase 2 | 47 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT06765928 | Selinexor Combined With Venetoclax Maintenance Therapy After Allo-HSCT | not yet recruiting | Phase 2 | 73 | Ruijin HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT02268253 | Tagraxofusp (SL-401) in Participants With Chronic Myelomonocytic Leukemia (CMML) and Myelofibrosis (MF) | completed | Phase 1 / Phase 2 | 82 | Stemline Therapeutics, Inc.INDUSTRY | 2 | Jan 6, 2025 | clinicaltrials |
| NCT04476199 | Venetoclax and Decitabine Assessment in Patients (≥60 - <75 Years) with Newly Diagnosed AML Eligible for Allo-SCT | active not recruiting | Phase 2 | 100 | Gruppo Italiano Trapianto di Midollo OsseoOTHER | 1 | Jan 6, 2025 | clinicaltrials |
| NCT04083170 | Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers | terminated | Phase 2 | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT06756152 | Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis | recruiting | Phase 2 / Phase 3 | 50 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT04160546 | Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)(ResToP) | active not recruiting | Phase 2 | 80 | Fundacion CRIS de Investigación para Vencer el CáncerOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT06741722 | Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML | recruiting | Phase 2 | 20 | Beijing 302 HospitalOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06746519 | BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia | recruiting | Phase 1 / Phase 2 | 135 | Chen SuningOTHER | 1 | Dec 24, 2024 | clinicaltrials |
| NCT02488408 | A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS | completed | Phase 1 / Phase 2 | 122 | BerGenBio ASAINDUSTRY | 4 | Dec 19, 2024 | clinicaltrials |
| NCT03770273 | Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis | completed | Phase 2 | 21 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Dec 17, 2024 | clinicaltrials |
| NCT00965224 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | completed | Phase 2 | 38 | Zwi BernemanOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT02807558 | A Biomarker-Directed Phase 2 Trial of Tamibarotene (SY-1425) in Participants With Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 2 | 155 | Syros PharmaceuticalsINDUSTRY | 2 | Dec 13, 2024 | clinicaltrials |
| NCT00452023 | Pegasys® in Patients With Myeloproliferative Diseases | completed | Phase 2 | 83 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT04582864 | Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) | terminated | Phase 2 | 11 | Washington University School of MedicineOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT02014558 | Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 265 | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Dec 3, 2024 | clinicaltrials |
| NCT03730012 | A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 11 | Astellas Pharma Global Development, Inc.INDUSTRY | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02927262 | A Study of ASP2215 (Gilteritinib), Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission | completed | Phase 2 | 98 | Astellas Pharma Global Development, Inc.INDUSTRY | 21 | Nov 26, 2024 | clinicaltrials |
| NCT04079296 | A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) | completed | Phase 1 / Phase 2 | 43 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 26, 2024 | clinicaltrials |
| NCT04147533 | Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid Leukemia(HALF) | active not recruiting | Phase 2 | 150 | Masaryk UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Mar 7, 2025source: clinicaltrials